TheraPHIX™,vivoPHIX™, genoPHIX™ and virusPHIX™
Choose a category:
RNAssist collaborates with Fiocruz and Bio-Manguinhos in Brazil on TheraPHIX™, an RNA stabilisation platform that enables liquid-stable mRNA-LNP vaccines effective at ambient temperatures, reducing cold-chain dependency and improving global vaccine access.
The rapid development of RNA vaccines during the COVID-19 pandemic saved millions of lives. However, one major challenge remains: RNA degrades quickly when exposed to heat, enzymes, or physical stress. This means that current RNA vaccines require deep freezing (-50°C or lower) to remain stable, making global distribution costly and logistically complex.
RNAssist is proud to announce the development of TheraPHIX™, a groundbreaking solution in mRNA vaccine stability. In collaboration with the Centre for Process Innovation (CPI) and with funding from Innovate UK, we have successfully created an ambient temperature liquid-stable mRNA-LNP formulation.
vivoPHIX™ has many applications – wherever your research may take you. Here are some photos from a recent project in South East Asia, where we were collecting bacteria from carnivorous plants. It can be difficult to get the required permits for collecting and transporting samples – whether it be bacteria, seeds or plants.
RNAssist technology supports a wide range of life science applications, including tissue fixation and dissociation, single-cell multiomics (scRNA-seq, CITE-seq), and virus inactivation and transport for enhanced diagnostic testing.
Follow us on LinkedIn
© RNAssist | www.RNAssist.com